Single dose subcutaneous treatment of an NCI-H1568 tumour xenograft model with compound 6 reduced median SMARCA2 levels in tumours by 90% relative to vehicle control-treated samples at 6 h after treatment, with slight recovery of the signal observed at 48 h after treatment, to a median decrease of 78% (Fig. 2f). The gene discussed is SMARCA2; the disease is neoplasm.